Chronic rapamycin treatment extends lifespan by activating nutrient-scarcity signaling pathways (GCN2/ISR, AMPK) rather than by directly reversing the age-related increase in Beclin-1/BCL-2 binding that suppresses autophagic flux. We hypothesize that rapamycin fails to disrupt the Beclin-1/BCL-2 complex in aged tissues; instead, it superimposes a parallel autophagy-inducing signal that operates alongside, but does not alleviate, this molecular brake. In contrast, genetic liberation of Beclin-1 (e.g., the F121A knock-in) constitutively reduces Beclin-1/BCL-2 binding, yielding autophagy activation independent of upstream stress cues. If the hypothesis is correct, combining low-dose rapamycin with a pharmacological BH3-mimetic that specifically disrupts Beclin-1/BCL-2 interaction should produce additive or synergistic lifespan extension, whereas rapamycin alone will not diminish the complex in old animals.

Testable predictions

1. Co-immunoprecipitation of Beclin-1 with BCL-2 from kidney, heart, and liver will show no significant reduction in old mice treated with rapamycin for 6 months compared with age-matched controls, whereas Beclin-1 F121A knock-in mice will display a marked decrease in binding.
2. Rapamycin treatment will increase phosphorylation of eIF2α and ATF4-dependent transcription, leading to elevated BCL-2 mRNA and protein levels, thereby reinforcing the brake.
3. Administration of a BH3-mimetic (e.g., ABT-737) at a dose that selectively disrupts Beclin-1/BCL-2 will lower complex formation in old mice; when combined with rapamycin, autophagic flux (measured by LC3-II turnover and p62 degradation) will exceed that achieved by either agent alone.
4. Lifespan studies will reveal that the rapamycin + BH3-mimetic combination yields a greater increase in median and maximal survival than rapamycin monotherapy, approximating the benefit seen in Beclin-1 F121A mice.

Experimental approach

• Cohorts: young (3 mo) and old (18 mo) C57BL/6J mice; old Beclin-1 F121A knock-in; old wild-type receiving rapamycin (14 ppm diet); old wild-type receiving rapamycin + BH3-mimetic; old wild-type receiving vehicle.
• Tissue collection at 3 and 6 months for co-IP, western blot of p-eIF2α, ATF4, BCL-2, LC3-II, p62.
• Autophagy flux assessed via lysosomal inhibition (chloroquine) chase.
• Survival monitored until natural death; statistical analysis using log-rank test.

Falsifiability If rapamycin significantly reduces Beclin-1/BCL-2 binding in aged tissues to the same extent as the genetic F121A mutation, or if the BH3-mimetic fails to enhance autophagy or lifespan when added to rapamycin, the hypothesis would be refuted. Conversely, confirmation of the predictions would support the view that rapamycin 'impersonates a harder life' without directly repairing the age-specific autophagy brake, thereby delineating two distinct routes to longevity: stress-signal mimetic versus damage-independent autophagy restoration.